MX365403B - Peptidos y metodos para usarlos. - Google Patents

Peptidos y metodos para usarlos.

Info

Publication number
MX365403B
MX365403B MX2014007799A MX2014007799A MX365403B MX 365403 B MX365403 B MX 365403B MX 2014007799 A MX2014007799 A MX 2014007799A MX 2014007799 A MX2014007799 A MX 2014007799A MX 365403 B MX365403 B MX 365403B
Authority
MX
Mexico
Prior art keywords
peptides
methods
same
autoimmune
inflammatory
Prior art date
Application number
MX2014007799A
Other languages
English (en)
Spanish (es)
Other versions
MX2014007799A (es
Inventor
Mogelsvang Soren
Gelber Cohava
Original Assignee
Serpin Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serpin Pharma Llc filed Critical Serpin Pharma Llc
Publication of MX2014007799A publication Critical patent/MX2014007799A/es
Publication of MX365403B publication Critical patent/MX365403B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2014007799A 2012-01-09 2013-01-07 Peptidos y metodos para usarlos. MX365403B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US201261699571P 2012-09-11 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (2)

Publication Number Publication Date
MX2014007799A MX2014007799A (es) 2014-10-24
MX365403B true MX365403B (es) 2019-05-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007799A MX365403B (es) 2012-01-09 2013-01-07 Peptidos y metodos para usarlos.

Country Status (10)

Country Link
US (6) US9951104B2 (https=)
EP (2) EP3381461B1 (https=)
JP (1) JP6416627B2 (https=)
AU (3) AU2013208293B2 (https=)
CA (2) CA3077804C (https=)
DK (2) DK3381461T3 (https=)
ES (2) ES2676028T3 (https=)
IL (1) IL233481A0 (https=)
MX (1) MX365403B (https=)
WO (1) WO2013106273A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
ES2913946T3 (es) 2013-07-08 2022-06-06 The Univ Of Utah Research Foundation Péptido y su uso en el tratamiento de trastornos inflamatorios
JP6806685B2 (ja) * 2014-09-16 2021-01-06 バイオインセプト、エルエルシー 急性放射線症候群を治療するための組成物及び方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160256611A1 (en) * 2015-03-04 2016-09-08 Microvention, Inc. Drug Delivery Device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017040287A1 (en) * 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
CA3004095A1 (en) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7370598B2 (ja) * 2018-05-02 2023-10-30 国立大学法人 新潟大学 ペプチド及びその使用
EP4003391A4 (en) 2020-07-06 2023-02-22 Serpin Pharma, LLC PEPTIDES AND METHODS OF USE THEREOF
AU2023260921A1 (en) * 2022-04-29 2024-11-07 Serpin Pharma, Llc Serpin peptide derivatives and methods of using the same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
DK0659073T3 (da) 1992-09-10 2002-03-11 Childrens Medical Center Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
DE69918090T2 (de) 1998-04-24 2005-06-16 University Of Florida, Gainesville Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1703916A2 (en) 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US20060141528A1 (en) * 2004-05-21 2006-06-29 Aebersold Rudolf H Compositions and methods for quantification of serum glycoproteins
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2007070981A1 (en) 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
EP1996215A2 (en) 2006-02-28 2008-12-03 Trustees Of Boston University Metabolic regulators and uses thereof
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
DK2193142T3 (da) 2007-08-30 2015-04-20 Curedm Group Holdings Llc Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US9005615B2 (en) 2010-05-06 2015-04-14 The Feinstein Institute For Medical Research Methods for treatment of inflammatory diseases
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
WO2017040287A1 (en) 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases

Also Published As

Publication number Publication date
JP2015504073A (ja) 2015-02-05
ES2676028T3 (es) 2018-07-16
US12291581B2 (en) 2025-05-06
CA2859777C (en) 2020-06-30
WO2013106273A2 (en) 2013-07-18
EP3381461A1 (en) 2018-10-03
JP6416627B2 (ja) 2018-10-31
AU2017258892A1 (en) 2017-11-30
US8975224B2 (en) 2015-03-10
US20170029465A9 (en) 2017-02-02
IL233481A0 (en) 2014-08-31
DK2802338T3 (en) 2018-06-14
CA3077804A1 (en) 2013-07-18
CA2859777A1 (en) 2013-07-18
WO2013106273A3 (en) 2013-12-19
US20250346632A1 (en) 2025-11-13
EP2802338A2 (en) 2014-11-19
MX2014007799A (es) 2014-10-24
CA3077804C (en) 2023-07-25
US20140378372A1 (en) 2014-12-25
AU2013208293A2 (en) 2016-01-28
BR112014016734A2 (pt) 2020-10-27
AU2013208293B2 (en) 2017-08-10
US20130274187A1 (en) 2013-10-17
DK3381461T3 (da) 2021-05-17
AU2017258892B2 (en) 2019-11-14
EP2802338B1 (en) 2018-03-07
US20150133375A1 (en) 2015-05-14
US10214562B2 (en) 2019-02-26
ES2871544T3 (es) 2021-10-29
US20200017550A1 (en) 2020-01-16
AU2019253814B2 (en) 2022-03-10
US20210188912A1 (en) 2021-06-24
AU2013208293A1 (en) 2014-06-26
HK1203161A1 (en) 2015-10-23
US9951104B2 (en) 2018-04-24
US10899797B2 (en) 2021-01-26
EP3381461B1 (en) 2021-03-10
AU2019253814A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
MX365403B (es) Peptidos y metodos para usarlos.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
PH12014501844B1 (en) Peptidomimetic macrocycles
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MY168032A (en) Warm-Cool Beauty Treatment Device
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX359769B (es) Metodos para descelularizar huesos.
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
MX361773B (es) Agentes de ligación a tlr3.
MX2014014781A (es) Extractos de tomillo silvestre y su uso.

Legal Events

Date Code Title Description
FG Grant or registration